Session

Penile cancer: New drugs and molecular insights on the horizon

Poster Session 19

  • Location:
    Room Paris (Hall B2, level 0)
  • Chairs:
     S.S. Minhas, London (GB)
     S. Osanto, Leiden (NL)
     C. Protzel, Rostock (DE)
  • Aims and objectives of this session

    This session presents results of local surgical laser treatment and new insights into molecular pathogenesis of penile cancer as well as new drugs to treat metastatic penile cancer.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
231
Role of penile Doppler US in the preoperative assessment of penile squamous cell carcinoma patients: Results from a large prospective multicenter European study

By: Bozzini G.1, Provenzano M.2, Romero Otero J.3, Margreiter M.4, Garcia Cruz E.5, Osmolorskij B.6, Verze P.7, Pavan N.8, Sanguedolce F.9, Buffi N.2, Guazzoni G.2, Taverna G.1

Institutes: 1Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, 2Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, 3Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, 4Vienna General Hospital, Dept. of Urology, Vienna, Austria, 5Hospital Clínic De Barcelona, Dept. of Urology, Barcelona, Spain, 6Lomonosov University Hospital, Dept. of Urology, Moscow, Russia, 7University Federico Il, Dept. of Urology, Naples, Italy, 8University of Trieste, Dept. of Urology, Trieste, Italy, 9Londo King’s College Hospital, Dept. of Urology, London, United Kingdom

232
Malignancy in biopsy proven penile lichen sclerosus

By: Zaid U., Lavien G., Potts B., Peterson A.

Institutes: Duke University, Dept. of Urology, Durham, United States of America

233
Carbon dioxide laser treatment of penile intraepithelial neoplasia

By: Vint R.1, Zreik A.1, Rewhorn M.1, Khan R.2, Hendry D.1

Institutes: 1Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 2Wishaw General Hospital, Dept. of Urology, Wishaw, United Kingdom

234
Outcomes of CO2 laser treatment for penile carcinoma in situ at a UK tertiary centre

By: McGuinness L.1, Veeratterapillay R.1, Conaway D.2, Teo L.2, Asterling S.2, Greene D.2, Keegan P.2

Institutes: 1Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 2Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom

235
Clinical usefulness of SPECT/CT during dynamic sentinel lymph node mapping in penile cancer

By: Omorphos S.1, Saad Z.2, Malone P.1, Nigam R.1, Bomanji J.2, Muneer A.1

Institutes: 1University College London Hospitals, Dept. of Urology, London, United Kingdom, 2University College London Hospitals, Dept. of Nuclear Medicine, London, United Kingdom

236
Surgical and oncological outcomes after video endoscopic inguinal lymphadenectomy (VEIL): Single institute series

By: Thyavihally Y., Rao H., Pednekar A., Kaushik T., Kalyan C., Parab M., Dharmadhikari N., Gulavani N., Patil A., Waigaonkar S.

Institutes: Kokilaben Dhirubhai Ambani Hospital, Dept. of Uro-oncology, Mumbai, India

237
Programmed death ligand 1 (PDL1) as a target for immunotherapy in penile carcinoma

By: Ottenhof S.1, Djajadiningrat R.1, De Jong J.2, Horenblas S.1, Jordanova K.2

Institutes: 1Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urologic Oncology, Amsterdam, The Netherlands, 2Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands

238
PIK3CA gene copy number and mRNA expression in invasive penile cancer

By: Adimonye A.1, Stankiewicz E.1, Kudahetti S.1, Rajab R.2, Corbishley C.2, Lu Y-J.1, Watkin N.3, Berney D.1

Institutes: 1Barts Cancer Institute, Dept. of Molecular Oncology, London, United Kingdom, 2St George’s Hospital, Dept. of Histopathology, London, United Kingdom, 3St George’s Hospital, Dept. of Urology, London, United Kingdom

239
Pan-HER trosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts)

By: Necchi A.1, Raggi D.1, Giannatempo P.1, Nicolai N.2, Colecchia M.3, Calareso G.4, Togliardi E.5, Crippa F.6, Mariani L.7, Perrone F.3, Pelosi G.3, Salvioni R.2, Sonpavde G.8

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pharmacy, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Clinical Epidemiology and Trials Organization, Milan, Italy, 8UAB Comprehensive Cancer Center, Dept. of Medical Oncology, Birmingham, United States of America

240
Distinct patterns of copy number aberrations in penile cancer

By: Rodney S.1, Feber A.1, Arya M.2, De Winter P.1, Saqib M.1, Nigam R1, Malone P.1, Tan S.1, Christodoulidou M.1, Sahdev V.1, Lechner M.3, Freeman A.4, Jameson C.1, Muneer A.2, Beck S.5, Kelly J.1

Institutes: 1University College London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, 2University College London Hospital, Dept. of Urology, London, United Kingdom, 3University College London Hospitals, Dept. of Histopathology, London, United Kingdom, 4University College London Hospital, Dept. of Histopathology, London, United Kingdom, 5University College London, UCL Cancer Institute, London, United Kingdom

241
Prognostic factors of adjuvant chemotherapy with taxane, cisplatin, and 5FU combination (TPF) in patients (pts) with nodal metastases of penile squamous cell carcinoma (PSCC)

By: Necchi A.1, Lo Vullo S.2, Nicolai N.3, Raggi D.1, Giannatempo P.1, Colecchia M.4, Torelli T.3, Catanzaro M.3, Piva L.3, Biasoni D.3, Stagni S.3, Mariani L.2, Salvioni R.3

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy

242
Comparison of survival outcomes for African−American and Caucasian men with advanced penile cancer in Florida

By: Ritch C.2, Pavan N.1, Rai S.2, Soodana-Prakash N.2, Balise R.3, Parekh D.2, Gonzalgo M.2

Institutes: 1University of Trieste, Dept. of Urology, Trieste, Italy, 2University of Miami Leonard M. Miller School of Medicine, Dept. of Urology, Miami, Florida, United States of America, 3University of Miami Leonard M. Miller School of Medicine, Dept. of Biostatistics, Department of Public Health Sciences, Miami, Florida, United States of America

243
Penile cancer cell lines of primary tumors and lymph node metastases are resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death

By: Naumann C.M.1, Hamann M.F.1, Van Der Horst C.1, Colberg C.1, Osmonov D.1, Engelmann D.2, Jünemann K.P.1, Kalthoff H.3, Trauzold A.3

Institutes: 1University Hospital Schleswig-Holstein, Dept. of Urology, Kiel, Germany, 2Institute of Experimental Gene Therapy and Cancer Research, Biomedical Research Center Rostock University Medical Center, Rostock, Germany, 3Institute For Experimental Cancer Research, Dept. of Molecular Oncology, Kiel, Germany

Summary and context
 S.S. Minhas, London (GB)